Company profile: Medivir
1.1 - Company Overview
Company description
- Provider of research-based pharmaceuticals focused on oncology and infectious diseases, leveraging protease inhibitor design and nucleotide/nucleoside science to address unmet medical needs. Portfolio includes MIV-818 for liver cancer, remetinostat for early-stage MF-CTCL, and VBX-1000 with positive proof-of-concept results. Also offers quarterly report conference calls and investor presentations.
Products and services
- MIV-818: Organ-targeted liver cancer drug that acts directly within hepatic tissue to minimize systemic toxicity, engineered to concentrate therapeutic activity in the diseased organ for enhanced tolerability
- VBX-1000: Proof-of-concept-validated drug candidate, previously known as MIV-701, exhibiting positive results in a Proof-of-Concept study
- Remetinostat: Skin-restricted therapy developed for early-stage MF-CTCL that remains active only on the skin, engineered to localize pharmacologic action to cutaneous tissue
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Medivir
Tetris Pharma
HQ: United Kingdom
Website
- Description: Provider of a pan-European platform to market a range of prescription products, offered by a UK-based speciality pharmaceutical company with extensive experience of launching products in the UK and across Europe, focused on areas of unmet clinical need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetris Pharma company profile →
Pro-Spectus
HQ: United States
Website
- Description: Provider of healthcare advisory services specializing in the pharmaceutical, medical device, and diagnostic healthcare industries, offering a Patient Access Program that enables patient and market access to therapies by optimizing the patient access journey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pro-Spectus company profile →
Therapak
HQ: United States
Website
- Description: Provider of diagnostic and medical device kitting services for clinical trials and healthcare, including protocol management, kit development, global distribution, and configurable collection kits, supported by PASSPORT online systems. Offers clinical supply packaging for temperature-sensitive shipments, specialized specimen collection and transport products, including customizable test-specific kits and temperature-controlled shipping systems, and an online hazardous materials training course.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therapak company profile →
Biodextris
HQ: Canada
Website
- Description: Provider of analytical and process development, early-phase clinical manufacturing, packaging, and scalable bioproduction services for vaccines and biologics. Offers quality control testing and validation to ensure regulatory compliance, with tailored development solutions for biotech and pharmaceutical companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biodextris company profile →
Icagen
HQ: United States
Website
- Description: Provider of ion channel-focused drug discovery platforms and services, including the Ion Channel Technology combining novel reagent generation, advanced biophysical analysis, and in silico tools; discovery-to-lead optimization services; and partnering with pharma/biotech to advance orally administered small-molecule therapeutics in neuroscience and chronic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Icagen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Medivir
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Medivir
2.2 - Growth funds investing in similar companies to Medivir
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Medivir
4.2 - Public trading comparable groups for Medivir
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →